Life sciences

Our advice is pragmatic, commercially-focused and rooted in deep industry knowledge. Many of the team are even former scientists or have worked in-house in life sciences companies.

Our experience is extensive and includes:

• Supporting a speciality pharmaceuticals group on the development and commercialisation of its lead drug candidates – putting in place a suite of supply chain and market access agreements, a Phase III clinical trial programme and setting up EU operations.
• Advising a Swiss-based biotech business on a range of technology in-licensing transactions.
• Supporting a Danish global pharma group on UK product compliance issues.
• Advising on a large number of fundraisings, including IPOs, for a number of pharma, device, diagnostic and digital health organisations.
• Providing strategic HR support to international pharma businesses.
• Supporting o2h on the creation of early stage EIS and SEIS investment funds to back biotech therapeutic opportunities.
• Helping a global pharma business with data compliance issues around a clinical trial.
• Advising IQ Capital on its follow-on investment in Fluidic Analytics, as part of a £21million fundraising.
• Helping Autolus relocate to the former BBC base at White City.
• Advising the Sanger Institute on strategic research collaborations with industry partners.

Our clients include:

• Global organisations
• Fast-growing companies in a wide range of therapeutic areas
• Universities involved in world-renowned research
• Leading research institutes
• Major research charities
• Government organisations 
• Sector fund managers

We take our role within the industry seriously and offer advice through our Life Science Law blog, our Sequence Newsletter and our twitter feed @MRSequencelaw. 

We also contribute to Mills & Reeve's technology and GDPR articles. 

For the latest in-depth views on the legal implications of Brexit, visit our Brexit pages.